Related references
Note: Only part of the references are listed.Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
R. M. Sobecks et al.
BONE MARROW TRANSPLANTATION (2012)
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning
Navneet S. Majhail et al.
BLOOD (2011)
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
Ted A. Gooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: Revised definitions to predict survival
Daniel Weisdorf et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model
Xu Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2007)
Busulphan in Blood and Marrow Transplantation: Dose, Route, Frequency and Role of Therapeutic Drug Monitoring
Christa Ellen Nath et al.
CURRENT CLINICAL PHARMACOLOGY (2007)
Medical progress: Hematopoietic stem-cell transplantation
EA Copelan
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Association of transplant center and physician factors on mortality after hernatopoietic stem cell transplantation in the United States
FR Loberiza et al.
BLOOD (2005)
The impact of low-dose busulfan on clonal dynamics in nonhuman primates
K Kuramoto et al.
BLOOD (2004)
Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy
C Lindley et al.
ANTI-CANCER DRUGS (2004)
Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences
B Fazeny-Dörner et al.
ANTI-CANCER DRUGS (2004)
HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen
JP Radich et al.
BLOOD (2003)
Nonmalignant late effects after allogeneic stem cell transplantation
G Socié et al.
BLOOD (2003)
Myeloablative conditioning regimens for AML allografts: 30 years later
V Gupta et al.
BONE MARROW TRANSPLANTATION (2003)
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission
MR Litzow et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
HJ Deeg et al.
BLOOD (2002)
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality
A Kashyap et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:: long-term follow-up of 4 randomized studies
G Socié et al.
BLOOD (2001)
Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells
RE Donahue et al.
HUMAN GENE THERAPY (2001)
Plasma concentration monitoring of busulfan - Does it improve clinical outcome?
JS McCune et al.
CLINICAL PHARMACOKINETICS (2000)
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite:: time interval influence on therapeutic efficacy and therapy-related toxicity
M Hassan et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
